Aquestive Therapeutics (AQST) Common Equity (2017 - 2026)

Aquestive Therapeutics' Common Equity history runs 10 years deep, the most recent figure standing at -$34.1 million for Q1 2026.

• On a quarterly basis, Common Equity rose 44.11% year-over-year to -$34.1 million in Q1 2026; TTM through Mar 2026 was -$34.1 million, a 44.11% increase from a year earlier, with the FY2025 full-year figure at -$33.7 million, up 44.04% from the prior year.
• Common Equity retreated to -$34.1 million in Q1 2026 per AQST's latest filing, from -$33.7 million in the prior quarter.
• Across five years, Common Equity topped out at -$4.1 million in Q3 2025 and bottomed at -$118.6 million in Q4 2022.
• The 5-year median for Common Equity is -$72.6 million (2025), against an average of -$72.0 million.
• Biggest YoY gain for Common Equity was 90.95% in 2025; the steepest drop was 104.6% in 2025.
• Year by year, Common Equity stood at -$118.6 million in 2022, then rose by 10.18% to -$106.5 million in 2023, then soared by 43.51% to -$60.2 million in 2024, then surged by 44.04% to -$33.7 million in 2025, then slipped by 1.16% to -$34.1 million in 2026.
• Per Business Quant, the three latest AQST Common Equity figures stand at -$34.1 million (Q1 2026), -$33.7 million (Q4 2025), and -$4.1 million (Q3 2025).